This product is provided solely for laboratory research use and is not a drug product
We know that as HR professionals, youre probably receiving a lot of questions about GLP-1s
The following symptoms warrant prompt medical attention and patients should contact their GP or seek urgent care if they experience: Severe or persistent abdominal pain , which may indicate pancreatitis a recognised risk with GLP-1-containing therapies [13] Jaundice, right upper quadrant pain, or fever , which may suggest gallbladder disease Signs of dehydration or reduced kidney function , such as dizziness, markedly reduced urine output, or confusion, particularly if vomiting or diarrhoea is prolonged Visual changes , particularly in individuals with pre-existing diabetic retinopathy Patients taking retatrutide alongside insulin or a sulfonylurea should be aware of an increased risk of hypoglycaemia (low blood sugar)
In the event of an overdose, it is reasonable to employ supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring (including obtaining an electrocardiogram), and institute supportive therapy as dictated by the patient's clinical status
GLP-1 agonists reduce LDL-C and ameliorate ox-LDLs proinflammatory injurious effects on vascular endothelial cells that include monocyte binding [59]
Rotating injection sites can minimize this concern
